Comparison of rivaroxaban and apixaban with other oral anticoagulant drugs Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Oct 20, 2026
DOI: https://doi.org/10.24292/01.MF.0226.15
Keywords:
anticoagulant therapy, apixaban, rivaroxaban, atrial fibrillation, venous thromboembolism, renal impairment, bleeding risk

Main Article Content

Alicja Uberna
Klinika Chorób Wewnętrznych, Nadciśnienia Tętniczego i Chorób Naczyń, Warszawski Uniwersytet Medyczny
Jacek Lewandowski
Klinika Chorób Wewnętrznych, Nadciśnienia Tętniczego i Chorób Naczyń, Warszawski Uniwersytet Medyczny

Abstract

This article discusses direct oral anticoagulants (DOACs), with particular emphasis on apixaban and rivaroxaban. Their use in selected clinical settings is presented, along with differences in their mechanisms of action and dosing regimens. Key characteristics of both agents that may influence therapeutic decision-making are highlighted. Rivaroxaban is distinguished by its once-daily dosing regimen, a broad range of clinical indications, including its unique use in vascular dosing, and a potentially beneficial effect on renal function. However, its limitation may be the requirement for administration with food at higher doses. Apixaban, on the other hand, is characterized by a particularly favorable safety profile, especially with regard to bleeding risk, as well as the absence of food-dependent absorption. Its limitation may be the need for twice-daily dosing, although sometimes it is considered an advantage. The role of DOACs in patients with comorbidities is also emphasized, along with the importance of individualized treatment based on patient-specific clinical characteristics.

Article Details

How to Cite
Uberna, A., & Lewandowski, J. (2026). Comparison of rivaroxaban and apixaban with other oral anticoagulant drugs. Medycyna Faktow (J EBM), 19(2(71), 247-252. https://doi.org/10.24292/01.MF.0226.15
Issue
Vol 19 No 2(71) (2026)
Section
Articles

Copyright by Medical Education. All rights reserved.

References

1. Kułach A, Gąsior Z. Leki przeciwkrzepliwe. In: Kardiologia. Podręcznik Polskiego Towarzystwa Kardiologicznego. Ponikowski P, Hoffman P, Witkowski A et al. (eds.). Via Medica, Gdańsk 2019: 108-10.
2. Eikelboom JW, Connolly SJ, Bosch J et al.; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017; 377(14): 1319-30.
3. Charakterystyka Produktu Leczniczego. Xarelto.
4. Charakterystyka Produktu Leczniczego. Pradaxa.
5. Charakterystyka Produktu Leczniczego. Eliquis.
6. Steffel J, Collins R, Antz M et al. Praktyczny przewodnik Europejskiego Stowarzyszenia Zaburzeń Rytmu Serca 2021 dotyczący stosowania doustnych leków przeciwkrzepliwych niebędących antagonistami witaminy K u pacjentów z migotaniem przedsionków. Polskie Towarzystwo Kardiologiczne, 2021.
7. Yao X, Abraham NS, Alexander GC et al. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016; 5(2): e003074.
8. Wilke T, Bauer S, Mueller S et al. Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. Patient. 2017; 10(1) :17-37.
9. Wilke T, Meinecke A, Schaefer B et al. Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment. Cardiol Res Pract. 2019; 2019: 5719624.
10. Yao X, Tangri N, Gersh BJ et al. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol. 2017; 70(21): 2621-32.
11. Yao X, Shah ND, Sangaralingham LR et al. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol. 2017; 69(23): 2779-90.
12. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883-91.
13. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139-51.
14. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981-92.
15. Castellucci LA, Chen VM, Kovacs MJ et al. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism. N Engl J Med. 2026; 394(11): 1051-60.
16. Martin AC, Thomas W, Mahir Z et al. Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study. Thromb Haemost. 2021; 121(2): 224-33.
17. Dobry P, Edwin SB, Haymart B et al. Treatment of atrial fibrillation and venous thromboembolism with factor Xa inhibitors in severely obese patients. J Thromb Haemost. 2024; 22(12): 3500-9.
18. Andrade JG, Krahn AD, Skanes AC et al. Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. Can J Cardiol. 2016; 32(6): 747-53.
19. Caroti KS, Becattini C, Carrier M et al. Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding. TH Open. 2023; 7(3): e206-16.